Jennison Associates LLC Revance Therapeutics, Inc. Transaction History

Jennison Associates LLC

$160 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$5.81 - $11.2 $201,816 - $389,043	34,736 Added 3.48%	1,032,352 $9.07 Million
Q3 2023 Oct 31, 2023	SELL	$11.47 - $25.07 $9.65 Million - $21.1 Million	-841,651 Reduced 45.76%	997,616 $11.4 Million
Q2 2023 Aug 03, 2023	BUY	$24.7 - $37.61 $5.09 Million - $7.75 Million	205,962 Added 12.61%	1,839,267 $46.6 Million
Q1 2023 Apr 26, 2023	SELL	$18.36 - $35.27 $7.21 Million - $13.9 Million	-392,720 Reduced 19.38%	1,633,305 $52.6 Million
Q4 2022 Feb 09, 2023	BUY	$18.32 - $30.66 $17.5 Million - $29.2 Million	953,790 Added 88.95%	2,026,025 $37.4 Million
Q3 2022 Nov 01, 2022	SELL	$14.33 - $28.47 $9.79 Million - $19.5 Million	-683,468 Reduced 38.93%	1,072,235 $29 Million
Q2 2022 Aug 02, 2022	SELL	$11.52 - $20.4 $7.9 Million - $14 Million	-685,583 Reduced 28.08%	1,755,703 $24.3 Million
Q1 2022 May 11, 2022	BUY	$12.36 - $20.31 $2.94 Million - $4.83 Million	237,722 Added 10.79%	2,441,286 $47.6 Million
Q4 2021 Feb 08, 2022	BUY	$12.46 - $27.87 $1.47 Million - $3.29 Million	118,038 Added 5.66%	2,203,564 $36 Million
Q3 2021 Nov 09, 2021	BUY	$25.78 - $33.21 $3.69 Million - $4.75 Million	142,946 Added 7.36%	2,085,526 $58.1 Million
Q2 2021 Aug 12, 2021	SELL	$26.8 - $31.84 $4.25 Million - $5.04 Million	-158,403 Reduced 7.54%	1,942,580 $57.6 Million
Q1 2021 May 11, 2021	SELL	$24.03 - $29.97 $2.42 Million - $3.01 Million	-100,525 Reduced 4.57%	2,100,983 $58.7 Million
Q4 2020 Feb 05, 2021	SELL	$23.41 - $28.34 $1.98 Million - $2.4 Million	-84,534 Reduced 3.7%	2,201,508 $62.4 Million
Q3 2020 Nov 04, 2020	BUY	$23.23 - $34.3 $3.71 Million - $5.47 Million	159,501 Added 7.5%	2,286,042 $57.5 Million
Q2 2020 Aug 06, 2020	BUY	$12.6 - $26.55 $5.34 Million - $11.3 Million	424,017 Added 24.91%	2,126,541 $51.9 Million
Q1 2020 May 06, 2020	BUY	$12.46 - $27.81 $21.2 Million - $47.3 Million	1,702,524 New	1,702,524 $25.2 Million
Q4 2018 Feb 06, 2019	SELL	$18.06 - $24.96 $627,639 - $867,434	-34,753 Closed	0 $0
Q3 2018 Nov 08, 2018	SELL	$23.55 - $30.1 $25.8 Million - $33 Million	-1,097,207 Reduced 96.93%	34,753 $864,000
Q2 2018 Aug 02, 2018	SELL	$27.45 - $33.35 $9.64 Million - $11.7 Million	-351,077 Reduced 23.67%	1,131,960 $31.1 Million
Q1 2018 Apr 20, 2018	BUY	$29.15 - $37.4 $18.2 Million - $23.4 Million	625,501 Added 72.94%	1,483,037 $45.7 Million
Q4 2017 Jan 25, 2018	BUY	$24.55 - $36.3 $11.8 Million - $17.4 Million	480,008 Added 127.15%	857,536 $30.7 Million
Q3 2017 Nov 03, 2017	BUY	$22.55 - $28.1 $8.51 Million - $10.6 Million	377,528	377,528 $10.4 Million

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

Black Rock Inc. New York, NY

8.57M
Shares

$22 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.73M
Shares

$14.7 Million
0.0% of portfolio
Franklin Resources Inc San Mateo, CA

4.78M
Shares

$12.3 Million
0.0% of portfolio
Fil LTD Hamilton, D0

4.19M
Shares

$10.8 Million
0.01% of portfolio
Alpine Associates Management Inc. Englewood Cliffs, NJ

4.16M
Shares

$10.7 Million
0.49% of portfolio

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.

Account